Nice

News

NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay

NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.

News

Scotland backs Aimovig for migraine after NICE says no

People suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig if they fail other therapies, according to the country’s cost-effectiveness

News

NICE recommends interim funding for Lilly's breast cancer dr...

Final draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving certain breast cancer patients an option that can delay c

News

NICE backs funding for MSD's diabetes drug Steglatro

NICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro in a final decision, after the company undercut rivals from the same

Views & Analysis

The shadow of Brexit on speed of access

No-one can miss the ongoing saga that is the UK’s exit from the European Union (EU).

News

NICE suggests lower threshold for hypertension treatment

Thousands more patients could benefit from drugs and treatment for hypertension under new guidance from NICE, which has just gone out for public consultation.